Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Pain
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266813
Licensor also grants the right to make and have made the Products outside the Territory for use within the Territory.
The term Product shall mean any parenterally administered dosage form containing paracetamol.
Paracetamol, also known as acetaminophen and APAP, is a medication used to treat pain and fever. It is typically used for mild to moderate pain relief. There is mixed evidence for its use to relieve fever in children. It is often sold in combination with other medications, such as in many cold medications.
IPSCIO Record ID: 266812
— an exclusive, even as to Licensor, royalty-bearing sublicense under the Licensor Rights with the right to sublicense, to import, use, sell and offer for sale Products in the Territory;
— an exclusive, even as to Licensor, sublicense under the Licensor Rights, with the right to sublicense, to make and have made the Products in the Territory solely for import, use, sale and offer for sale within the territory or import and use in clinical trials in the Clinical Study Countries as permitted; and
— an exclusive, even as to Licensor, sublicense under the Licensor Rights, with the right to sublicense, to make and have made the Products anywhere in the world solely for import, use, sale and offer for sale within the Territory, subject to the limitations set forth in an Agreement relating to parenteral paracetamol, or import or use in Licensees clinical trials in the Clinical Study Countries as permitted;
— a non-exclusive license under the Licensors Patents, with the right to sublicense, to import, use, sell and offer for sale Products in the Territory;
— a non-exclusive license under the Licensor Patents, with the right to sublicense, to make and have made the Products in the Terriitory solely for import, use, sale and offer for sale within the Territory;
— a non-exclusive license under the Licensor Know-How, with the right to sublicense, to make and have made the Products anywhere in the world solely for use and sale within the Territory and import and use in clinical trials in the Clinical Study Countries as permitted; and,
— a non-exclusive right to use, copy, translate, display and distribute, improve and make derivative works of the Licensor Technology Documentation for the purpose of making and having made the Products consistent with the license set forth above with respect to the Licensor Know-How.
Product means any parenterally administered dosage form containing paracetamol, or any Derivative thereof, alone or in combination with one or more other drugs, and for which the manufacture, use or sale in a country in the Territory would otherwise infringe any of the Licensed Patents or Licensors Patents but for the license rights granted by Licensor herein, and/or incorporates or uses to any material extent any Licensed Know-How and/or any parenterally administered dosage form containing paracetamol, or any Derivative thereof, alone or in combination with one or more other drugs that is manufactured by a process that incorporates or uses to any material extent any Licensor Know-How.
Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers.
IPSCIO Record ID: 280936
A non-exclusive license under the Licensor Patents, with the right to sublicense as provided in this agreement, to import, use, sell and offer for sale Products in the Territory; provided, however, that the license granted in this paragraph shall not grant any right to the composition of matter of any Other Chemical Entity, or the right to import, use, sell or offer for sale any Other Chemical Entity or to any use not claimed by the Licensor Patents.
A non-exclusive license under the Licensor Know-How, with the right to sublicense as provided in this agreement, to make and have made the Products anywhere in the world solely for (1) use and sale within the Territory and (2) import and use in clinical trials in the Clinical Study Countries as permitted.
A non-exclusive right to use, copy, translate, display and distribute (subject to any confidentiality obligations), improve and make derivative works of the Licensor Technology Documentation for the purpose of making and having made the Products consistent with the license set forth above with respect to the Licensor Know-How.
Product shall refer to any parenterally administered dosage form containing paracetamol (or any Derivative thereof) alone or in combination with one or more other drugs.
Pharmatop Patents means the Licensed Patents (as such term is defined in the Pharmatop License Agreement) filed or issued in the Territory and licensed to Licensor under the Pharmatop License Agreement.
U.S. Patent #6,593,331 – Method for treatment of pain
U.S. Patent #6,511,982 – Treatment of pain
Licensor Rights means (i) Licensor’s rights under the Pharmatop Patents and Pharmatop Know-How with respect to the Products in the Territory licensed to Licensor under the Pharmatop License Agreement during the term of this Agreement, subject to the limitations, terms and conditions set forth in the Pharmatop License Agreement and (ii) the right granted to Licensor of the Pharmatop License Agreement to make and have made the Products outside the Territory for use within the Territory.
IPSCIO Record ID: 4717
Dex is in a class of drugs called alpha-2 adrenergic agonists, which produce their effects by selectively activating the alpha-2 adrenergic receptors in the body and produce a broad range of effects depending on the specific drug and the alpha-receptors it activates, including anti-hypertensive, analgesic and sedative effects. In particular, Dex has demonstrated sedative, analgesic and anxiolytic properties in multiple preclinical and clinical studies, including the new drug application, or NDA, studies for Precedex®.
5217718 & 5124157 TRANSDERMAL ADMINISTRATION OF DEXMEDETOMIDINE – Method and device for administering dexmedetomidine transdermally
“Field†means the treatment of pain in humans, including mild, moderate, or severe acute and chronic pain, alone or as an adjunct.
IPSCIO Record ID: 26233
IPSCIO Record ID: 1208
Licensor grants an exclusive license under the Technology, including foreign counterparts and equivalents of patent rights to the extent any exist, to manufacture and have manufactured Products outside the Territory in order to import, use and Commercialize Products in the Field in the Territory, including the right to grant sublicenses.
Licensor grants an exclusive license to use the Trademarks to Commercialize, including to advertise, promote and distribute, the Products in the Field in the Territory.
Licensor grants an exclusive license to exploit the Domain Names in connection with the Products.
This agreement includes a non-exclusive grant back from Licensee to Licensor.
Aversion® Composition means a composition having a gel forming polyethylene oxide, sodium lauryl sulfate, and crospovidone.
Product A means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 7.5mg with each tablet containing the Aversion® Composition with niacin at 30mg.
Product B means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 10.0mg with each tablet containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.
Product C means an immediate release Future Product in three tablet strengths hydrocodone bitartrate 5.0mg, 7.5mg, and 10.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.
Product D means an immediate release Future Product [in three tablet strengths hydromorphone HCl 2.0mg, 4.0mg, and 8.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg.
Trademarks means Aversion®, Acurox™, and Acuracet™.
The patents are for Methods and Compositions for Deterring Abuse of Opioid.
Acurox®, Acuracet® (oxycodone HCI/niacin/APAP) Tablets, Vycavert® (hydrocodone bitartrate/niacin/APAP) Tablets and a fourth undisclosed opioid analgesic product candidate utilizing our proprietary Aversion® Technology.
The Licensee has an option to License in the territory all future opioid analgesic products developed utilizing Aversion® Technology. The Agreement provides that Licensor or Licensee may develop additional opioid analgesic product candidates utilizing our Aversion® Technology and, if Licensee exercises its option to License such additional product candidates, they will be subject to the milestone and royalty payments and other terms of the Agreement.
The drug is part of a class of opioid analgesic products for treatment for moderate to severe acute pain.
The Licensor is responsible, using commercially reasonable efforts, for all Acurox® Tablet development activities through FDA approval of a 505(b)(2) NDA, for which our expenses are reimbursed to us by the Licensee. After NDA approval the Licensee will be responsible for manufacturing and commercializing Acurox® Tablets in the U.S.
